ReviewFolia microbiologica2026
Quorum quenching pathoblockers from bacteria: an alternative approach for bacterial infection management.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance in bacterial pathogens has reached a crisis stage and has led to fears of a “post-antibiotic era”. To combat this, current approach focuses on indirect attack on bacteria by disrupting their communication system, quorum sensing (QS). This system comprises small diffusible signalling molecules activating expression of myriad genes that control an array of functions, including biofilm formation, production of virulence factors and development of antibiotic resistance. Gram-positive bacteria utilise peptide derivatives of these signalling molecules, whereas Gram-negative bacteria employ fatty acid derivatives. Majority of bacteria utilise both types to regulate expression of target gene. Recent research has prioritised identifying several compounds from diverse sources that can hinder the signalling systems responsible for bacterial virulence and pathogenicity. QS inhibitor (QSI) should target the signalling circuit and have no effect on other bacterial systems. Major mechanisms involved in QS inhibition include inhibition of signal molecule synthesis, inactivation/enzymatic degradation of signal molecules, interference with signal receptor, and blocking signal transduction cascades. QSI thus decreases/completely inhibits production of virulence factors. Bacterial products as QSI constitute a promising approach in developing anti-virulence therapies, providing a new avenue for combating bacterial infections parallelly improving effectiveness of traditional antibiotics. Exploring a diverse array of bacterial products like secondary metabolites, cell-free extracts, bacteriocins, biosurfactants, and enzymes as QSIs are gaining prominence due to their selectivity, reduced propensity to induce resistance, and capacity to target multiple pathogens. This review comprehends reported research outcomes from this domain in the recent past and highlights the need of future clinical/translational studies.
Indexed as
Identifiers
41428149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.